Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze NBIX Neurocrine Biosciences, Inc.. Please read: https://finlab.finance/en/setup?stock=NBIX

No install, open FinLab Studio

NBIX

Neurocrine Biosciences, Inc. Healthcare As of 2026-07-31 Updated daily after market close

strong quality, premium valuation.

2 active signals

52-week adjusted-price high Filed revenue acceleration

This page refreshes daily after the close. Add Neurocrine Biosciences, Inc. to your watchlist to track signal changes on your next visit.

Is Neurocrine Biosciences, Inc. a buy? Fundamentals and valuation first

Quality is top-tier. Operating margin ranks above roughly 80% of the liquid US common-stock universe. TTM ROE is about 19.6%.
Valuation is expensive. TTM P/E is in the 79th percentile, above most peers.
Recent volatility is moderate. 60-day annualized volatility is near the 43th percentile. Average 20-day dollar volume is about $232.7M.
Signals are active now. 52-week adjusted-price high, Filed revenue acceleration currently holds; the tables below show what followed in this stock’s own history.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

25 historical occurrences (since 2017-08-09)

120 days after: historical avg +6.15%

20-day +0.12%

60-day +1.63%

120-day +6.15%

20-day

60-day

120-day

Win

62.5%

52.4%

Sample

Median

+1.91%

+6.01%

+3.04%

Excess

+0.44%

-0.97%

+0.77%

Beat mkt rate

62.5%

52.4%

42.9%

Over 21 occurrences, 120-day forward avg gained 6.15%, beat the market by 0.77 pts; win rate 52.4%.

Filed revenue acceleration

Active · now 28.591560971565944%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

11 historical occurrences (since 2018-04-30)

120 days after: historical avg +8.95%

20-day +0.47%

60-day +4.07%

120-day +8.95%

20-day

60-day

120-day

Win

45.5%

54.5%

55.6%

Sample

Median

-2.61%

+3.32%

+10.78%

Excess

+2.24%

+2.44%

+6.33%

Beat mkt rate

63.6%

54.5%

55.6%

Over 9 occurrences, 120-day forward avg gained 8.95%, beat the market by 6.33 pts; win rate 55.6%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

0-20 +13% Now

20-40 +11.7%

40-60 +17.8%

60-80 +3.5%

80-100 +1.6%

PE percentile band	Sample days	240-day avg return	Median	Win rate	Avg excess (vs index)
0-20 You are here	164	+13%	+17%	77.4%	-0.3%
20-40	384	+11.7%	+10.7%	70.8%	-9.2%
40-60	203	+17.8%	+14.4%	75.9%	+5.9%
60-80	77	+3.5%	-0.7%	45.5%	-8.2%
80-100	62	+1.6%	+1.5%	67.7%	-12%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 25.70, placing it in the 13.1 own-history percentile, inside the 0-20 bucket.

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation

Momentum

Cheap (own-history bottom third)

Middle

Expensive (own-history top third)

60-day momentum up

Now

+4.1%

Win rate 51% Excess -4.9%

361d

+6.1%

Win rate 72.8% Excess +1.4%

228d

-4.7%

Win rate 12.9% Excess -8.6%

62d

60-day momentum down

+9.7%

Win rate 57.8% Excess +1.9%

204d

+17.5%

Win rate 83.9% Excess +12.1%

155d

Insufficient data
(0d)

Currently in “Cheap (own-history bottom third) × 60-day momentum up”: across 361 historical days, 120-day forward avg gained 4.1%, win rate 51%, lagged the market by 4.9%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 97,878 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.26%, a 58.3% positive-return rate, and +2.90 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

20 times historically; 60-day forward avg +5.83%, win rate 63.2%, beating the market by -0.38 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

18 times historically; 60-day forward avg +4.01%, win rate 64.7%, beating the market by +0.83 pts on average.

Method and limits

Returns use us_price:adj_close, adjusted for splits and dividends where available.
Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.